Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. We have been very impressed by their vision and the relevance of their platform.”.

Genome 105

Genome Genomics Medicine Development 105

Drug Discovery World

FEBRUARY 19, 2024

At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus. Preliminary data show that the surrogate metric of protection (RVNA≥0.5)

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Pharmaceutical Technology

AUGUST 24, 2022

Mode rna has submitted an application to the US Food and Drug Administration (FDA) to obtain emergency use authorization (EUA) for mRNA-1273.222, its BA.4/BA.5 As against a 50µg booster dose of mRNA-1273 in priorly uninfected subjects, mRNA-1273.214 demonstrated superior neutralising antibody response against Omicron BA.1 1 subvariant.

Vaccination 130

Vaccination Vaccine Gene Therapy Antibody 130

Delveinsight

SEPTEMBER 23, 2021

The biotech has evolved a T-cell receptor-like antibody to damage a selected immune checkpoint in oncology. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising.

RNA 61

RNA Gene Therapy Gene Protein 61

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Pharma is also keen to access next generation RNA platforms, such as self-amplifying RNAs derived from the genomes of positive-strand RNA viruses.

RNA 52

RNA Pharma Companies Antibody Life Science 52

Drug Discovery World

DECEMBER 21, 2023

DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Read the article – Three trends in the antibody-drug conjugate (ADC) market Expert view: What’s next for cell and gene therapy?

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict. Integrated analytical services for pharmaceuticals.

Development 130

Development Production Manufacturing Vaccination 130

Drug Discovery World

MAY 13, 2024

RA: How can rational design approaches help advance vaccine development? MA: Regarding vaccine development specifically, and the role my team plays in the development of cryogenic electron microscopy (cryo-EM) technology, we see the study and dissemination of virus structures, and the proteins that comprise them, as vital to vaccine design.

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Drug Discovery World

MAY 17, 2024

First use of click chemistry in CAR-T cell therapy shows promise Acepodia has announced promising preliminary data from its Phase I dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin’s lymphoma (NHL).

Gene Therapy 52

Gene Therapy Gene Drugs In-Vivo 52

Drug Discovery World

JANUARY 13, 2023

Alliance to develop circular RNA-based therapeutics . Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. . Collaboration to identify up to 10 novel target-antibody pairs . The top stories: . Cambrian expands fibrosis pipeline

Drugs 52

Drugs Antibody RNA Engineer 52

Drug Discovery World

OCTOBER 11, 2023

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances ’ will feature an expert panel discussion on new drug discovery and development concepts and tools in cancer research. The free two-hour Summit, hosted by DDW, will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET.

Research 52

Research Antibody RNA Engineer 52

Drug Discovery World

OCTOBER 5, 2023

Experts and thought leaders in cancer research, precision medicine and immunotherapy will describe the latest research and the role of technology to help discover targets, develop cancer therapeutics and vaccines and, get to market faster. What are the best research tools to aid development of new treatments and vaccines?

Research 52

Research Antibody Medicine RNA 52

Pharmaceutical Technology

JULY 5, 2022

The team also found that the oral compound, RG7834, developed by Hoffmann-La Roche, hindered replication at a crucial step, preventing the virus from infecting liver cells. They also noted how the oral treatment could lower the ability of the virus to cause liver injury in mice genetically modified to develop HAV infection and disease.

Protein 130

Protein RNA Genome Genomics 130

pharmaphorum

OCTOBER 22, 2020

The company has joined forces with Atea Pharmaceuticals to develop, manufacture and distribute Atea’s investigational oral direct-acting antiviral AT-527. AT-527 works by blocking the viral RNA polymerase enzyme needed for viral replication. The post Roche to co-develop remdesivir rival in partnership with Atea appeared first on.

Development 65

Development Branding Manufacturing RNA 65

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Roots Analysis

OCTOBER 13, 2023

As a result, in late nineties, the conjugation of drug with biological entities such as antibodies emerged as a possible solution for targeting earlier undruggable entities. However, it was not until 2000 when the first drug conjugate in the form of antibody drug conjugate (ADC) was approved by the USFDA.

Drugs 40

Drugs Antibody RNA Genetics 40

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

pharmaphorum

JANUARY 7, 2022

NI006 is an antibody that binds to the misfolded forms of the transthyretin protein that form the fibrils, and cause them to be cleared away by immune cells like macrophages. Antisense drug eplontersen – which is forecast to become a $1 billion-plus product if approved – is being developed for both ATTR cardiomyopathy and polyneuropathy.

Antibody 116

Antibody Licensing Licensing Protein 116

Delveinsight

AUGUST 26, 2021

Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Roots Analysis

DECEMBER 12, 2023

As a result, innovators came up with the idea of magic bullets, antibody drug conjugates (ADCs). It is comprised of three components, namely antibody, drug and linker. The antibody is conjugated to the drug via a linker molecule. The antibody is conjugated to the drug via a linker molecule. Components of an ADC?

Antibody 40

Antibody Manufacturing Drugs RNA 40

The Pharma Data

JANUARY 20, 2021

based Gritstone Oncology is developing a novel COVID-19 vaccine based on adenovirus and messenger-RNA technology designed to combat future variants of the coronavirus. Emeryville, Calif.-based

Vaccination 52

Vaccination Vaccine RNA Protein 52

The Pharma Data

SEPTEMBER 10, 2020

According to the data, the vaccine candidate conferred “protective anti-viral effects” in rhesus macaque monkeys, as well as concomitant high neutralising antibody titers and a TH1-biased cellular response in both the monkeys and in mice. The study and the data are currently subject to peer review.

Immune Response 52

Immune Response Vaccination Vaccine RNA 52

The Pharma Data

AUGUST 3, 2021

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

pharmaphorum

OCTOBER 16, 2020

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. It started human testing of a protein subunit vaccine with partner GlaxoSmithKline last month. Russia approves second shot.

Trials 98

Trials Vaccination Vaccine Antibody 98

Drug Discovery World

MAY 26, 2023

The top stories: Biopharma investment drops by nearly 50% in 2022 Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. million to develop the next generation of small molecule drugs against disease areas of high clinical need.

Drugs 52

Drugs DNA RNA Manufacturing 52

XTalks

FEBRUARY 3, 2022

According to the IDA Ireland (Investment Development Agency), a non-commercial, semi-state inward investment promotion agency that promotes foreign direct investment into Ireland, the project is awaiting approval as the company prepares to submit a planning application with Limerick City and County Council in the next few weeks.

Manufacturing 52

Manufacturing RNA Life Science Antibody 52

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

JUNE 22, 2023

This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies. “We The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. The full manuscript of the preclinical data is available on the pre-print server bioRxiv. “In

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

SEPTEMBER 16, 2020

Both of these vaccines are based on RNA and in phase 3 and phase 1 testing, respectively. The amount due to be awarded by Dessau-based IDT Biologika – whose non-replicating viral vector shot is further back in development – is still being discussed, according to German broadcaster Deutsche Welle.

Vaccination 86

Vaccination Vaccine RNA Trials 86

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.

Development 52

Development DNA Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130

Genetics Gene Expression DNA Antibody 130

BioSpace

NOVEMBER 20, 2022

Former Theranos CEO Elizabeth Holmes will serve 11 years in prison on four counts of fraud, according to her sentencing by a federal judge in a California courtroom on Friday afternoon.

Antibody 73

Antibody Medicine Research Clinical Trials 73

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Silverback Therapeutics

RNA 52

RNA Antibody Life Science Protein 52